The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Key claim: The Mito-Frail trial is testing whether MitoQ supplementation can improve central and cerebral vascular function, reduce oxidative stress, and enhance mobility and cognitive performance in frail older adults.
Abstract
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question[s] it aims to answer are:
- To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction
- To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels
- To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Why this matters
Mito-Frail is one of the few registered human trials directly testing a mitochondria-targeted antioxidant (MitoQ) against frailty-relevant vascular, mobility, and cognitive endpoints, rather than surrogate biomarkers in healthy volunteers. Because prior MitoQ human work has been dominated by short vascular-function studies in healthier adults, a frailty-population readout would be an unusually direct test of whether the mitochondrial-ROS-to-endothelial-dysfunction chain translates to a clinically vulnerable group. Until results publish, this remains a protocol-stage signal — the mechanistic pitch outruns the outcome data.